<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">CALCIPOTRIENE</span><br/>(cal-ci'po-tri-een)<br/><span class="topboxtradename">Dovonex<br/></span><b>Classifications:</b> <span class="classification">skin and mucous membrane agent</span>; <span class="classification">vitamin d analog</span><br/><b>Prototype: </b>Calcitriol<br/><b>Pregnancy Category: </b>C<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>0.005% ointment and cream</p>
<h1><a name="action">Actions</a></h1>
<p>Calcipotriene is a synthetic vitamin D<sub>3</sub> analog for the treatment of moderate plaque psoriasis. The scaly red patches of psoriasis are caused by abnormal growth and
         production of skin cells known as keratinocytes.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Calcipotriene controls psoriasis by inhibiting proliferation of keratinocytes, reducing the number of polymorphonuclear leukocytes
         (PMNs) in the skin cells, and decreasing the number of epithelial cells.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>Treatment of moderate plaque psoriasis.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Hypersensitivity to calcipotriene, hypercalcemia or vitamin D toxicity.</p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Dermatoses other than psoriasis; patients &gt;65 y old; pregnancy (category C), lactation. Safety and efficacy in children not
         established.
      </p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle"></span><br/><span class="rdage">Adult:</span> <span class="rdroute">Topical</span> Apply a thin layer to affected area once or twice daily<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Topical</span><br/><ul>
<li>A thin layer should be applied to the affected skin and rubbed in gently and completely.</li>
<li>Calcipotriene should not be applied to the face.</li>
<li>Wash hands before and after application of medication.</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">Skin:</span> Facial dermatitis, burning, stinging, erythema, folliculitis, mild transient itching. 
      <h1><a name="interactions">Interactions</a></h1> No clinically significant interactions established. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Approximately 6% absorbed systemically. <span class="typehead">Onset:</span> 1 wk. <span class="typehead">Peak:</span> 8 wk. <span class="typehead">Duration:</span> 4 wk. <span class="typehead">Metabolism:</span> Recycled via liver. <span class="typehead">Elimination:</span> Excreted in bile. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Observe reductions in scaling, erythema, and lesion thickness indicating a positive therapeutic response.</li>
<li>Significant reduction in psoriatic lesions usually occurs following 1 wk of treatment. Marked improvement is generally noted
            by the 8th wk of treatment.
         </li>
<li>Lab tests: Monitor periodically serum calcium, phosphate, and calcitriol levels, during long-term therapy.</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Treatment with calcipotriene may be indefinite, as reappearance of psoriatic lesions is common following discontinuation of
            the drug.
         </li>
<li>Adverse effects may include burning and stinging with drug application; these are usually transient.</li>
<li>Do not mix calcipotriene with any other topical medicine.</li>
<li>Report appearance of facial dermatitis (erythema and scaling around mouth and nose).</li>
<li>Do not breast feed while taking this drug without consulting physician.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>